ClinicalTrials.gg
RecruitingNCT05316883BiCSUpdated Jan 20, 2026

Biomarkers in Clozapine-responding Schizophrenia

A Phase 4 interventional study of Clozapine in Schizophrenia and Psychosis, sponsored by Jimmi Nielsen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Jimmi Nielsen · Phase 4, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Feb 2021; still recruiting 5 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies testing clozapine in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. Clozapine · Schizophrenia.

Planned enrollment
7th of 37
200 · median 41
Started
2021
with 1 other
Phase 4
21 of 37
6 open now
Registered
31st of 37
by date

Among the 37 studies testing clozapine in Schizophrenia, this one is the 7th largest by planned enrollment, is one of 2 that started in 2021, is one of 21 in phase 4, and was the 31st registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 37 studies testing clozapine in Schizophrenia are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About clozapine

Clozapine: first FDA approval 1989 (CLOZARIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing clozapine in Schizophrenia, or all of them as a file.
02

Study summary

The outline of the current project is to establish a cohort of patients with treatment refractory schizophrenia eligible for clozapine, to identify clinical and biological characteristics of clozapine responding patients. Patients will be offered treatment with clozapine according to national clinical guidelines. Before clozapine is initiated, patients will be offered a thoroughly neurobiological examination, and re-examination will be carried out after 12 weeks of treatment. The primary focus of the examinations will be immunological markers and autoantibodies in the blood and cerebrospinal fluid, permeability of the blood-brain barrier and magnetic resonance imaging of structural, neurochemical and functional brain changes.

Read the detailed description

Patients will be examined before and after 12 weeks of treatment with clozapine

Examinations at baseline and follow up will be:

  • Clinical ratings
  • Blood inflammatory markers
  • Inflammatory markers in cerebro spinal fluid
  • MRI : examination of grey \& white matter, glutamate and GABA in Anterior Cingulate cortex and glutamate in thalamus,
  • selected cognitive measures
03

Conditions studied

  • Schizophrenia
  • Psychosis
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • According to ICD-10 fulfill diagnostic criteria for schizophrenia (F20.x), chronical paranoid psychoses (F22), Schizoaffective psychoses (F25) or other non-organic psychoses (F28/F29);
  • Age 18-65 years;
  • Legally competent;
  • Stabil antipsychotic treatment during last month
  • Being treatment according to TRIPP-guidelines (Howes et al. 2017) defined as having tried at least two antipsychotic drugs in sufficient dosage (≥600 mg chlorpromazine equivalent) for a sufficient time (≥ 6 weeks) without sufficient symptom improvement (still a moderate level of positive symptoms).
  • Recreational use of substances is allowed as long as it does not interfere with compliance
  • Fertile females must use safe (spiral or any hormonal contraception).

Exclusion criteria

Exclusion Criteria:

  • Involuntarily psychiatric admittance during the study
  • Substance abuse that interfere with compliance
  • Pregnancy (will be verified by urine-HCG-test in fertile females)
  • Toxic or idiosyncratic agranulocytosis in the past
  • Reduced bone marrow function according to blood samples
  • According to information from patient and available files, noUncontrolled

    • Current uncontrolled epilepsy
    • Current circulatory collapse and / or CNS depression for any cause
    • Current severe kidney, heart or liver disease
    • Current paralytic ileus
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Other
    clozapine treatment

    Open label clozapine will be given to all participants in clinical doses adjusted to sideeffects and clinical effect

    Drug: Clozapine

Interventions

  • clinical doses adjusted to sideeffects and clinical effect

06

What researchers measure

Primary outcomes

  1. Qalb

    Quotient albumin (Qabl) in cerebrospinal fluid (CSF) compared to plasma

    Time frame: Baseline

  2. Change in Qalb

    Change in quotient albumin in cerebrospinal fluid compared to plasma

    Time frame: Baseline and after 12 weeks

  3. Change in IL-6 and TGF-beta

    Change in interleukin 6 (IL-6) and transcription growth factor beta (TGF-beta)

    Time frame: Baseline and after 12 weeks

Secondary outcomes

  1. Change in FA, MD, AD and RD

    Change in fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD)

    Time frame: Baseline and after 12 weeks

  2. Change in cortical thickness as measured with FreeSurfer

    Change in cortical thickness as measured with FreeSurfer

    Time frame: Baseline and after 12 weeks

  3. Change in glutamate in ACC and thalamus measured with MTI

    Change in glutamate in anterior cingulate cortex (ACC) and thalamus measured with magnetic transfer imaging (MTI)

    Time frame: Baseline and after 12 weeks

07

Study locations

1 of 1 sites recruiting
  • Mental Health Services Glostrup, Unit for Complicated Schizophrenia
    Glostrup Municipality, Denmark 2600, Denmark
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2029, 106 months after the start.

Of 71 non-industry phase 4 interventional studies under Schizophrenia, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 106 months is above that.

Counting every sponsor, half of 88 studies reached it within 39 months; a quarter within 20 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2020
First posted
Apr 7, 2022
StartActual
Feb 28, 2021
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05316883
Lead sponsor
Jimmi Nielsen
Responsible party
Jimmi Nielsen (Professor, Copenhagen University Hospital, Hvidovre) — Sponsor-investigator
First posted
Apr 7, 2022
Start date
Feb 28, 2021
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Jan 20, 2026

Study contacts

Jimmi Nielsen, PhD
Contact
jimmi.nielsen@regionh.dk
4538640885
Mette Nielsen, PhD
Contact
mette.oedegaard.nielsen@regionh.dk
Jimmi Nielsen, PhD
principal investigator · Mental health Service, Glostrup

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clozapine

Start the discussion